Product Description
Mechanisms of Action: NOS1 Inhibitor,COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nicox
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Kidney Diseases|Type 2 Diabetes|Peripheral Arterial Disease|Intermittent Claudication|Arterial Occlusive Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PAOD | P2 |
Completed |
Intermittent Claudication|Peripheral Arterial Disease|Arterial Occlusive Diseases |
2005-04-01 |
2019-03-19 |
Treatments |
|
| NCX4016-X-204 | P2 |
Terminated |
Kidney Diseases|Type 2 Diabetes |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|